Health Kick Podcast: Accurately measuring cognition offers massive upside to clinicians and drug makers; CGS has the tech
Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.
In this episode Tim chats with Brad O’Connor, managing director and CEO of Cogstate (ASX:CGS).
Cogstate is a neuroscience technology company focused on improving brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare.
The company began an impressive recovery in March, rising some 30 per cent off the back of impressive 2020 sales figures.
On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.
Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!
Related Topics
Related Stories
UNLOCK INSIGHTS
Discover the untold stories of emerging ASX stocks.
Daily news and expert analysis, it's free to subscribe.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
